3,640 Shares in Novartis AG (NYSE:NVS) Purchased by Financial Engines Advisors L.L.C.

Financial Engines Advisors L.L.C. acquired a new position in shares of Novartis AG (NYSE:NVS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,640 shares of the company's stock, valued at approximately $354,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVS. Bryn Mawr Capital Management LLC boosted its position in Novartis by 0.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company's stock worth $1,254,000 after acquiring an additional 100 shares during the last quarter. Rothschild Investment LLC grew its holdings in Novartis by 0.6% in the fourth quarter. Rothschild Investment LLC now owns 16,682 shares of the company's stock valued at $1,623,000 after purchasing an additional 101 shares during the period. Meridian Wealth Management LLC grew its stake in shares of Novartis by 2.6% during the 4th quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company's stock valued at $405,000 after buying an additional 106 shares during the period. Angeles Wealth Management LLC grew its position in Novartis by 3.5% during the fourth quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company's stock valued at $316,000 after acquiring an additional 110 shares during the period. Finally, Heritage Family Offices LLP increased its stake in Novartis by 1.9% during the fourth quarter. Heritage Family Offices LLP now owns 6,107 shares of the company's stock worth $594,000 after acquiring an additional 112 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

A number of research analysts have weighed in on NVS shares. UBS Group reaffirmed a "neutral" rating on shares of Novartis in a research report on Thursday, February 13th. Barclays reaffirmed an "underweight" rating on shares of Novartis in a research report on Monday, February 3rd. StockNews.com raised shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. HSBC lowered Novartis from a "hold" rating to a "reduce" rating in a research report on Wednesday, December 4th. Finally, Deutsche Bank Aktiengesellschaft raised Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $123.38.

Novartis Stock Performance

NVS traded down $1.99 during trading hours on Tuesday, hitting $109.49. 1,954,308 shares of the stock were exchanged, compared to its average volume of 1,501,737. The stock has a market cap of $223.80 billion, a price-to-earnings ratio of 18.62, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. The stock has a 50-day simple moving average of $108.40 and a 200-day simple moving average of $107.06. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were issued a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is presently 42.69%.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.